Trilogy Capital’s Tandem Diabetes Care TNDM Stock Holding History

Trilogy Capital’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-12	Closed	-$1K	–	520
2018 Q3	$1K	Buy	+12	New	+$419	﹤0.01%	591

Other funds holding TNDM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Trilogy Capital's TNDM Position: Q4 2018 in Review

Trilogy Capital sold out of Tandem Diabetes Care (TNDM) in Q4 2018, closing a stake of 12 shares — an estimated $1K sold.

Trilogy Capital first reported a position in TNDM in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 200 funds tracked by Wall St. Rank hold TNDM as of Q4 2018.

Trilogy Capital reported no remaining Tandem Diabetes Care position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 12 Tandem Diabetes Care shares in Q4 2018, an estimated $1K.
Trilogy Capital first reported a position in Tandem Diabetes Care in Q3 2018 and held it in 1 quarter.
Trilogy Capital's Tandem Diabetes Care position peaked at $1K in Q3 2018.
200 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.